VEGFR
All Product Categories
-
VEGFR Inhibitors
(337)
View all products
-
VEGFR Agonists
(5)
View all products
-
VEGFR Antagonists
(4)
View all products
-
VEGFR Activators
(7)
View all products
-
VEGFR Modulators
(6)
View all products
-
VEGFR Chemical
(1)
View all products
-
VEGFR Inducer
(1)
View all products
-
VEGFR Ligands
(3)
View all products
-
VEGFR Related Products (403)
Related Products (403)
-
GW701427A
0 ImagesCat. No.: HY-160684CAS No.: 433224-56-7GW701427A is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.12 μM and 603 nM, respectively. GW701427A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays.
-
PD-1/PD-L1-IN-69
0 ImagesCat. No.: HY-189430PD-1/PD-L1-IN-69 is an orally active PD-L1 dimerization inducer and FAK phosphorylation inhibitor (IC50 = 18.7 nM for human PD-1/PD-L1 interaction). PD-1/PD-L1-IN-69 blocks the PD-1/PD-L1 interaction by stabilizing dimerization within the PD-L1 dimerization pocket, and inhibits VEGF-A-induced FAK phosphorylation and angiogenesis, thereby enhancing immune-mediated tumor cell death. PD-1/PD-L1-IN-69 can be used for research on colon adenocarcinoma.
-
CEP-5214
0 ImagesCat. No.: HY-15334CAS No.: 402857-39-0CEP-5214, derived from a new indenopyrrolocarbazole template, is a potent inhibitor of vascular endothelial growth factor R2 (VEGF-R2) tyrosine kinase. Structurally, it features optimal substitutions at positions 9 (ethoxymethyl) and 12 (hydroxypropyl) on the indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-one scaffold, leading to high potency against VEGF-R2 (IC50 8 nM). Compound 21 (CEP-5214) exhibits low-nanomolar inhibition of human VEGF-R tyrosine kinases (IC50 4 nM for VEGF-R2/KDR), with good selectivity over other kinases. The compound demonstrated significant cellular and in vivo antitumor activity across various models and advanced into phase I clinical trials as a water-soluble prodrug (CEP-7055) to enhance oral bioavailability.
-
AGN-745 sodium
0 ImagesCat. No.: HY-177612ASynonyms: AGN-211745 sodium; Sirna-027 sodiumAGN-745 sodium is a chemically modified siRNA targeted to VEGFR-1. It is used for the study of Macular degeneration.
-
VEGFR-2-IN-20
0 ImagesCat. No.: HY-147779CAS No.: 2404581-25-3
-
Antiproliferative agent-54
0 ImagesCat. No.: HY-135216CAS No.: 1240322-54-6Antiproliferative agent-54 (Compound 6z) is the inhibitor for multiple kinases, such as ABL WT, B-RAF, EGFR, HCK, LYN A and SRC with IC50 of 6-50 nM. Antiproliferative agent-54 inhibits proliferation of several cancer cell, inhibits HUVEC and HepG2, with EC50 of 34 and 38 nM. Antiproliferative agent-54 exhibits good pharmacokinetic characteristics in rats.
-
VEGFR-2-IN-52
0 ImagesCat. No.: HY-161966CAS No.: 3046428-94-5VEGFR-2-IN-52 (compound 14d) is a potent VEGFR-2 inhibitor with an IC50 value of 191.1 nM. VEGFR-2-IN-52 decreases the protein expression of p-VEGFR-2, MMP9, p-ERK1/2 and p-MEK1. VEGFR-2-IN-52 shows cytotoxicity. VEGFR-2-IN-52 induces apoptosis and cell cycle arrest at G0/G1 phase. VEGFR-2-IN-52 increases the levels of ROS.
-
Jolkinolide A
0 ImagesJolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells.
-
VEGFR/PARP-IN-1
0 ImagesCat. No.: HY-155965CAS No.: 3010256-54-6VEGFR/PARP-IN-1 (Compound 14b) is a VEGFR/PARP dual inhibitor (IC50s: 191 nM and 60.9 nM respectively). VEGFR/PARP-IN-1 inhibits DNA damage repair, induces cell apoptosis, and arrests cell in the G2/M phase. VEGFR/PARP-IN-1 has good antiproliferative efficacy against BRCA wild-type breast cancer cells (IC50: 4.1 and 3.5 μM for MDA-MB-231 and MCF-7 cells). VEGFR/PARP-IN-1 is an antitumor and anti-metastasis agent.
-
Mollugin (Standard)
0 ImagesMollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway.
-
Tafetinib analogue 1
0 ImagesCat. No.: HY-114588CAS No.: 1032265-67-0Synonyms: SIM010603 analogue 1Tafetinib (SIM010603) analogue 1 is an analog of the tyrosine kinase receptor inhibitor Tafetinib (SIM010603)..
-
ML786
0 ImagesCat. No.: HY-14979CAS No.: 1237586-97-8
-
VEGFR-2-IN-51
0 ImagesCat. No.: HY-159510VEGFR-2-IN-51 (compound 19) is an orally active dual-target inhibitor of VEGFR-2 (IC50=15.33 μM) and tubulin (IC50=0.76 μM) with anti-tumor activity. VEGFR-2-IN-51 induces tumor cell apoptosis by reducing mitochondrial membrane potential and increasing reactive oxygen species (ROS) levels. VEGFR-2-IN-51 exerts anti-angiogenic effects by blocking the VEGFR-2/PI3K/AKT signaling pathway. In addition, VEGFR-2-IN-51 has significant anti-proliferative activity against the gastric cancer cell line MGC-803 (IC50=0.005 μM).
-
CEP-11981 tosylate
0 ImagesCat. No.: HY-16135ACAS No.: 901128-79-8Synonyms: ESK981 tosylate; BOL 303213X tosylateCEP-11981 (tosylate) (ESK981 (tosylate), BOL 303213X (tosylate)) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects.
-
FLT3/VEGFR2-IN-1
0 ImagesCat. No.: HY-168493FLT3/VEGFR2-IN-1 (Compound 26) is a FLT3/VEGFR2/HDAC inhibitor with IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM for FLT3, VEGFR2, and HDAC1, respectively. FLT3/VEGFR2-IN-1 can inhibit the phosphorylation of STAT3 and ERK1/2 and the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 has anti-tumor activity and can be used for the research of acute myeloid leukemia.
-
(rac)-ZK-304709
0 ImagesCat. No.: HY-19471CAS No.: 1010440-84-2(rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET.
-
VEGFR-2/c-Met-IN-1
0 ImagesCat. No.: HY-149674CAS No.: 3017162-02-3VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and c-Met with IC50s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity.
-
VEGFR-2-IN-50
0 ImagesCat. No.: HY-161855VEGFR-2-IN-50 (Compound 10f) is a VEGFR-2 inhibitor and apoptosis inducer, with an IC50 value of 0.33 μM. VEGFR-2-IN-50 (Compound 10f) has growth inhibitory activity on MCF-7 and MDA-MB-231 breast cancer cell lines, with IC50 values of 19.86 μM and 10.88 μM, respectively, which is expected to be used in the study of breast cancer diseases.
